ASX:ACW Actinogen Medical (ACW) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free ACW Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume275,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield8.76%Price TargetN/A Stock AnalysisStock Analysis Get Actinogen Medical alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Actinogen MedicalActinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.Read More Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. ACW Stock News HeadlinesApril 22, 2024 | finance.yahoo.comEnrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trialApril 16, 2024 | msn.comActinogen treats first subject in Alzheimer’s disease therapy trialApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | finanznachrichten.deActinogen Medical Limited: First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trialApril 15, 2024 | finance.yahoo.comFirst patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trialMarch 12, 2024 | finance.yahoo.comInvestors in Actinogen Medical (ASX:ACW) have unfortunately lost 53% over the last yearFebruary 28, 2024 | proactiveinvestors.com.auActinogen Medical delivers strong half-year results as it develops novel therapyFebruary 27, 2024 | au.investing.comActinogen Medical on track to deliver two key Phase 2 trial results in next 18 monthsApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 22, 2024 | msn.comDiagnosing mental disorder through sleep: How TrivarX could capture this huge research marketJanuary 30, 2024 | finance.yahoo.comWill Actinogen Medical (ASX:ACW) Spend Its Cash Wisely?January 24, 2024 | finance.yahoo.comPositive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancyDecember 13, 2023 | morningstar.comActinogen Medical Ltd ACWNovember 28, 2023 | finance.yahoo.comActinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024November 10, 2023 | finance.yahoo.comShareholders May Be A Bit More Conservative With Actinogen Medical Limited's (ASX:ACW) CEO Compensation For NowOctober 13, 2023 | finance.yahoo.comActinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, BostonSeptember 26, 2023 | finance.yahoo.comActinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business updateMay 31, 2023 | finance.yahoo.comActinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International ConventionMay 24, 2023 | travel.usnews.comThe 5 Best Travel Medical Insurance Plans for 2023April 3, 2023 | uk.finance.yahoo.comInvestors in Actinogen Medical (ASX:ACW) have made a strong return of 215% over the past three yearsMarch 30, 2023 | finance.yahoo.comActinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conferenceMarch 27, 2023 | finance.yahoo.comActinogen Medical Limited (ATGGF)January 12, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn SituationDecember 22, 2022 | finance.yahoo.comFDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trialDecember 14, 2022 | finance.yahoo.comActinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trialDecember 1, 2022 | reuters.comActinogen Medical LtdOctober 25, 2022 | uk.finance.yahoo.comInvestors in Actinogen Medical (ASX:ACW) have made a splendid return of 212% over the past three yearsSee More Headlines Receive ACW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinogen Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ACW CUSIPN/A CIKN/A Webwww.actinogen.com.au Phone61 2 8964 7401FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.02% Return on Assets-59.24% Debt Debt-to-Equity Ratio0.37 Current Ratio5.42 Quick Ratio13.73 Sales & Book Value Annual Sales$4.79 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.38 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,330,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.28 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Steven G. Gourlay ) (Age 64)FRACP, M.B.A., MBBS (M.D., Ph.D., MD, CEO & Director Comp: $514.44kDr. Dana C. Hilt M.D. (Age 71)Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board Comp: $385.4kProf. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Head of Clinical Pharmacology & Lead Physician and DepressionMr. William Edward Souter BComIPAA, LLB (Adel), Chief Financial OfficerMr. Michael RobertsHead of Investor Relations & Corporate CommunicationsDr. Fujun Li Ph.D.Head of ManufacturingMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersMalcolm McComasSold 3,000,000 sharesTotal: $87,000.00 ($0.03/share)Nicki VasquezSold 5,500,000 sharesTotal: $170,500.00 ($0.03/share)Geoffrey BrookeSold 4,900,000 sharesTotal: $112,700.00 ($0.02/share)Geoffrey BrookeSold 474,058 sharesTotal: $11,851.45 ($0.03/share) ACW Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Actinogen Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinogen Medical investors own include Dynavax Technologies (DVAX), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB), EQTEC (EQT) and Exact Sciences (EXAS). This page (ASX:ACW) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinogen Medical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
